Merck & Co., Inc. (MRK) Options Risk Score
Real-time risk analysis for MRK options traders — updated every 30 minutes.
Data last updated: 2026-07-23
Run a full MRK options risk analysis
See the complete risk breakdown — news catalysts, SEC filings, legal proceedings, earnings overlap, IV vs HV, options flow and Expected Move — all in one scan.
Scan MRK Now — Free →
Is it risky to sell options on Merck & Co., Inc. (MRK) right now?
Merck & Co., Inc. (MRK) currently scores 76 out of 100 for options catalyst risk (HIGH) over a 4-week expiry window. What pushes it there: an upcoming earnings report, 9 recent news items, 3 active legal filings and 22 clinical-trial catalysts, all landing inside the 4-week window. Anything at 70 or above counts as HIGH, meaning the premium on MRK is at least partly compensation for a scheduled event rather than pure time value. It says nothing about direction — only that something is on the calendar.
MRK shows an IV Rank of 74 — implied volatility is near the top of its own one-year range, so MRK options are historically expensive, which favours premium-selling strategies, with a current implied volatility of about 36%. Read IV Rank alongside the catalyst score: it says how expensive MRK options are, while the score says whether that price is justified by a scheduled event.
MRK is scheduled to report earnings on 2026-08-04, which falls inside a typical monthly options expiry — expect elevated implied volatility into the event and an IV crush afterward.
TickerRisk provides risk scoring for informational purposes only. This is not financial advice. Options trading involves substantial risk of loss. Full disclaimer